SNN0029

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	4

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02269436 (ClinicalTrials.gov)	January 2015	8/10/2014	A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029in P ...	A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracere ...	Amyotrophic Lateral Sclerosis	Drug: sNN0029 infusion solution	Newron Sweden AB	NULL	Terminated	18 Years	75 Years	Both	11	Phase 1	Belgium;Netherlands
2	NCT01999803 (ClinicalTrials.gov)	September 2014	22/11/2013	A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS	A Phase I, Randomised, Double-blind, Placebo-controlled Study in Patients With Amyotrophic Lateral S ...	Amyotrophic Lateral Sclerosis	Drug: sNN0029;Drug: Placebo	Newron Sweden AB	NULL	Terminated	18 Years	75 Years	Both	15	Phase 1	Belgium;Netherlands
3	NCT01384162 (ClinicalTrials.gov)	June 2009	23/6/2011	An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration ...	An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration ...	Amyotrophic Lateral Sclerosis	Drug: sNN0029	Newron Sweden AB	Medtronic;ICON Clinical Research	Terminated	18 Years	75 Years	Both	15	Phase 1/Phase 2	Belgium
4	NCT00800501 (ClinicalTrials.gov)	December 2008	29/11/2008	A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029to Patients With ...	A Double-blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular ...	Amyotrophic Lateral Sclerosis	Drug: sNN0029;Drug: Placebo	Newron Sweden AB	Medtronic;ICON Clinical Research	Completed	18 Years	75 Years	Both	18	Phase 1/Phase 2	Belgium

First Previous1Next Last